Results 11 to 20 of about 277,930 (211)

Nanoparticles in Targeted Alpha Therapy [PDF]

Nanomaterials, 2020
Recent advances in the field of nanotechnology application in nuclear medicine offer the promise of better therapeutic options. In recent years, increasing efforts have been made on developing nanoconstructs that can be used as carriers for immobilising alpha (α)-emitters in targeted drug delivery.
Agnieszka Majkowska-Pilip, Weronika Gawęda, Kinga Żelechowska-Matysiak, Kamil Wawrowicz, Aleksander Bilewicz   +4 more
openaire   +3 more sources

Revisiting the Radiobiology of Targeted Alpha Therapy [PDF]

Frontiers in Medicine, 2021
Targeted alpha therapy (TAT) using alpha particle-emitting radionuclides is in the spotlight after the approval of 223RaCl2 for patients with metastatic castration-resistant prostate cancer and the development of several alpha emitter-based radiopharmaceuticals.
Pouget, Jean-Pierre, Constanzo, Julie
openaire   +3 more sources

PARP1-targeted alpha therapy enhances target expression. [PDF]

EJNMMI Res
Abstract Graphical abstract
Babazada H, Martorano P, Lee H, Geng S, Batra V, Maris JM, Pryma DA, Gitto SB, Farwell MD.   +8 more
europepmc   +4 more sources

Actinium-225 in Targeted Alpha Therapy. [PDF]

J Med Phys
The utilization of actinium-225 ( 225 Ac) radionuclides in targeted alpha therapy for cancer was initially outlined in 1993. Over the past two decades, substantial research has been conducted, encompassing the establishment of 225 Ac production methods,
Rahman AKMR, Babu MH, Ovi MK, Zilani MM, Eithu IS, Chakraborty A.   +5 more
europepmc   +4 more sources

Microdosimetry for Targeted Alpha Therapy of Cancer [PDF]

Computational and Mathematical Methods in Medicine, 2012
Targeted alpha therapy (TAT) has the advantage of delivering therapeutic doses to individual cancer cells while reducing the dose to normal tissues. TAT applications relate to hematologic malignancies and now extend to solid tumors. Results from several clinical trials have shown efficacy with limited toxicity.
Chen-Yu Huang, Susanna Guatelli, Bradley M. Oborn, Barry J. Allen   +3 more
openaire   +4 more sources

Alpha emitting nuclides for targeted therapy

Nuclear Medicine and Biology, 2021
Targeted alpha therapy (TAT) is an area of research with rapidly increasing importance as the emitted alpha particle has a significant effect on inducing cytotoxic effects on tumor cells while mitigating dose to normal tissues. Two significant isotopes of interest within the area of TAT are thorium-227 and actinium-225 due to their nuclear ...
Jasmine L, Hatcher-Lamarre, Vanessa A, Sanders, Mohammed, Rahman, Cathy S, Cutler, Lynn C, Francesconi   +4 more
openaire   +3 more sources

An overview of targeted alpha therapy

Tumor Biology, 2011
The effectiveness of targeted α-therapy (TAT) can be explained by the properties of α-particles. Alpha particles are helium nuclei and are ~8,000 times larger than β(-)-particles (electrons). When emitted from radionuclides that decay via an α-decay pathway, they release enormous amounts of energy over a very short distance.
Kim, Young-Seung, Brechbiel, Martin W.
openaire   +4 more sources

Targeted Alpha Therapy: Current Clinical Applications [PDF]

Cancer Biotherapy and Radiopharmaceuticals, 2020
α-Emitting radionuclides have been approved for cancer treatment since 2013, with increasing degrees of success. Despite this clinical utility, little is known regarding the mechanisms of action of α particles in this setting, and accurate assessments of the dosimetry underpinning their effectiveness are lacking.
Liberal, Francisco D C Guerra, O'Sullivan, Joe M, McMahon, Stephen J, Prise, Kevin M   +3 more
openaire   +3 more sources

Targeting Alpha-Synuclein as a Therapy for Parkinson’s Disease [PDF]

Frontiers in Molecular Neuroscience, 2019
Parkinson's disease (PD) is one of the most common neurodegenerative disorders with a global burden of approximately 6.1 million patients. Alpha-synuclein has been linked to both the sporadic and familial forms of the disease. Moreover, alpha-synuclein is present in Lewy-bodies, the neuropathological hallmark of PD, and the protein and its aggregation ...
Fields, CR, Bengoa-Vergniory, N, Wade-Martins, R   +2 more
openaire   +4 more sources

Thrombolytic Therapy Targeting Alpha 2-Antiplasmin [PDF]

Circulation, 2017
Article, see p 1011 Tissue plasminogen activator (tPA) has been used as a thrombolytic agent for many years based on its high fibrin specificity, which contributes to its safety in thrombolytic therapy.1,2 Despite the favorable results associated with tPA treatments, its use is limited to the first 4.5 hours after the onset of event, and the dosage ...
Tetsumei, Urano, Yuko, Suzuki
openaire   +2 more sources